Regeneron Pharmaceuticals Inc. buy Cantor Fitzgerald
Start price
29.10.25
/
50%
€558.60
Target price
29.10.26
€635.29
Performance (%)
14.01%
Price
18:58
€636.00
Summary
This prediction is currently active. The prediction currently has a performance of 14.01%. Dividends of €0.88 are taken into consideration when calculating the performance. This prediction currently runs until 29.10.26. The prediction end date can be changed by Cantor_Fitzgerald at any time. Cantor_Fitzgerald has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 6.613% | 6.613% |
| iShares Core DAX® | 0.060% | 1.215% |
| iShares Nasdaq 100 | -3.065% | -0.519% |
| iShares Nikkei 225® | -2.094% | -3.066% |
| iShares S&P 500 | -1.657% | -0.069% |
Comments by Cantor_Fitzgerald for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Cantor Fitzgerald from $678.00 to $740.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat